BioNTech and partner Pfizer warned on Monday that they had no evidence that their jointly developed vaccine will continue to protect against COVID-19 if the booster shot is given later than tested in trials.
“The safety and efficacy of the vaccine has not been evaluated on different dosing schedules as the majority of trial participants received the second dose within the window specified in the study design,” the companies said in a joint statement, referring to prime and a booster shots given three weeks apart.
Read more: WHO approves Pfizer vaccine for emergency use, paving way for rollout to countries in need
- Calgary cyclotron to make radiopharmaceuticals for fighting cancer expected by 2029
- Severely disabled 18-year-old denied AISH benefits — until media made aware
- Edmonton plane pull supports Hope Air flights taking Canadians to medical appointments
- GLP-1, ADHD medication costs leading surge in drug insurance claims: report
“There is no data to demonstrate that protection after the first dose is sustained after 21 days.”
Get weekly health news
Germany was considering on Monday whether to allow a delay in administering the second dose to make scarce supplies go further after a similar move by Britain last week. Separately, Denmark approved a delay of up to six weeks between the first and second shots of the vaccine.
Comments
Want to discuss? Please read our Commenting Policy first.